Drug Profile
Research programme: L-ergothioneine analogues - GT Biopharma
Alternative Names: L-ergothioneine analogues research programme - GT BiopharmaLatest Information Update: 10 Aug 2017
Price :
$50
*
At a glance
- Originator OXIS International
- Class
- Mechanism of Action Antioxidants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Adult respiratory distress syndrome; Chemotherapy-induced damage; Eye disorders; HIV infections; Radiation injuries
Most Recent Events
- 07 Aug 2017 Oxis International is now called GT Biopharma
- 13 Jul 2011 Discontinued - Preclinical for Adult respiratory distress syndrome in USA (unspecified route)
- 13 Jul 2011 Discontinued - Preclinical for Chemotherapy induced damage (Prevention)/Chemoprotection in USA (unspecified route)